
Nicholas A Tritos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1853166/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature, 1998, 396, 670-674.	27.8	1,085
2	Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. Journal of Comparative Neurology, 1998, 402, 442-459.	1.6	783
3	Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. Journal of Clinical Investigation, 2001, 107, 379-386.	8.2	578
4	Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4078-4085.	3.6	376
5	Management of Cushing disease. Nature Reviews Endocrinology, 2011, 7, 279-289.	9.6	181
6	Leptin: its role in obesity and beyond. Diabetologia, 1997, 40, 1371-1379.	6.3	145
7	Two important systems in energy homeostasis: melanocortins and melanin-concentrating hormone. Neuropeptides, 1999, 33, 339-349.	2.2	144
8	Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus. Diabetes, 1998, 47, 1687-1692.	0.6	130
9	Melanin-Concentrating Hormone Receptor Is a Target of Leptin Action in the Mouse Brain. Endocrinology, 2001, 142, 680-686.	2.8	121
10	Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. European Journal of Endocrinology, 2019, 181, 211-219.	3.7	116
11	Serum Ghrelin Levels in Response to Glucose Load in Obese Subjects Postâ€Gastric Bypass Surgery. Obesity, 2003, 11, 919-924.	4.0	113
12	Circulating Insulin Concentrations, Smoking, and Alcohol Intake Are Important Independent Predictors of Leptin in Young Healthy Men. Obesity, 1998, 6, 179-186.	4.0	105
13	The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 118-126.	3.6	102
14	Characterization of melanin concentrating hormone and preproorexin expression in the murine hypothalamus. Brain Research, 2001, 895, 160-166.	2.2	88
15	Comparison of aortic elasticity determined by cardiovascular magnetic resonance imaging in obese versus lean adults. American Journal of Cardiology, 2003, 91, 195-199.	1.6	86
16	Effects of Recombinant Human Growth Hormone Therapy in Obesity in Adults: A Metaanalysis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 130-137.	3.6	82
17	Effects of recombinant human growth hormone therapy in adults with Prader–Willi syndrome: a metaâ€analysis. Clinical Endocrinology, 2012, 77, 86-93.	2.4	80
18	Characterization of Expression of Hypothalamic Appetite-Regulating Peptides in Obese Hyperleptinemic Brown Adipose Tissue-Deficient (Uncoupling Protein-Promoter-Driven Diphtheria Toxin A) Mice ¹ . Endocrinology, 1998, 139, 4634-4641.	2.8	78

#	Article	IF	CITATIONS
19	Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management. Endocrine, 2016, 52, 427-440.	2.3	77
20	Effects of Recombinant Human Growth Hormone Therapy on Bone Mineral Density in Adults With Growth Hormone Deficiency: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 852-860.	3.6	75
21	Recombinant human growth hormone: old and novel uses. American Journal of Medicine, 1998, 105, 44-57.	1.5	71
22	The Physiology and Potential Clinical Applications of Ghrelin, a Novel Peptide Hormone. Mayo Clinic Proceedings, 2006, 81, 653-660.	3.0	60
23	Melanin-Concentrating Hormone Receptor Is a Target of Leptin Action in the Mouse Brain. Endocrinology, 2001, 142, 680-686.	2.8	60
24	Risk Factors for Lower Extremity Arterial Disease in Non-insulin-dependent Diabetic Persons. Diabetic Medicine, 1996, 13, 243-246.	2.3	55
25	Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3770-3777.	3.6	55
26	American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Update on Growth Hormone Stimulation Testing and Proposed Revised Cut-Point for the Glucagon Stimulation Test in the Diagnosis Of Adult Growth Hormone Deficiency. Endocrine Practice, 2016, 22, 1235-1244.	2.1	55
27	Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary, 2014, 17, 150-156.	2.9	53
28	Effects of Growth Hormone on Bone. Progress in Molecular Biology and Translational Science, 2016, 138, 193-211.	1.7	51
29	Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective. Pituitary, 2020, 23, 327-337.	2.9	49
30	Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2081-2094.	3.6	47
31	Characterization of the peroxisome proliferator activated receptor coactivator 1 alpha (PGC $1\hat{1}\pm$) expression in the murine brain. Brain Research, 2003, 961, 255-260.	2.2	45
32	Cardiac Structure and Function in the Obese: A Cardiovascular Magnetic Resonance Imaging Study. Journal of Cardiovascular Magnetic Resonance, 2003, 5, 431-438.	3.3	44
33	Predictors of Hypopituitarism in Patients with Traumatic Brain Injury. Journal of Neurotrauma, 2015, 32, 1789-1795.	3.4	44
34	Estradiolâ€Induced Anorexia Is Independent of Leptin and Melanin oncentrating Hormone. Obesity, 2004, 12, 716-724.	4.0	41
35	Endocrine manifestations of Erdheim-Chester disease (a distinct form of histiocytosis). Journal of Internal Medicine, 1998, 244, 529-535.	6.0	37
36	Cushing's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 124, 221-234.	1.8	36

#	Article	IF	CITATIONS
37	American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: A Neuroendocrine Approach to Patients With Traumatic Brain Injury. Endocrine Practice, 2015, 21, 823-831.	2.1	36
38	Growth hormone and bone. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 415-422.	2.3	33
39	Update on radiation therapy in patients with Cushing's disease. Pituitary, 2015, 18, 263-268.	2.9	33
40	Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience. American Surgeon, 2000, 66, 73-9.	0.8	33
41	Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clinical Endocrinology, 2012, 77, 430-438.	2.4	32
42	Bone microarchitecture and estimated bone strength in men with active acromegaly. European Journal of Endocrinology, 2017, 177, 409-420.	3.7	32
43	Current management of Cushing's disease. Journal of Internal Medicine, 2019, 286, 526-541.	6.0	32
44	Advances in medical therapies for Cushing's syndrome. Discovery Medicine, 2012, 13, 171-9.	0.5	32
45	Cerebrospinal Fluid Ghrelin Is Negatively Associated with Body Mass Index. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2943-2946.	3.6	31
46	Unreplaced Sex Steroid Deficiency, Corticotropin Deficiency, and Lower IGF-I Are Associated with Lower Bone Mineral Density in Adults with Growth Hormone Deficiency: A KIMS Database Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1516-1523.	3.6	31
47	Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2018-2029.	3.6	31
48	Asymptomatic 'big' hyperprolactinemia in two men with pituitary adenomas. European Journal of Endocrinology, 1998, 138, 82-85.	3.7	30
49	Association between ghrelin and cardiovascular indexes in healthy obese and lean men. Clinical Endocrinology, 2004, 60, 60-66.	2.4	30
50	MRI texture analysis as a predictor of tumor recurrence or progression in patients with clinically non-functioning pituitary adenomas. European Journal of Endocrinology, 2018, 179, 191-198.	3.7	30
51	Diabetes Insipidus With Deficient Thirst: Report of a Patient and Review of the Literature. American Journal of Kidney Diseases, 2008, 51, 851-859.	1.9	28
52	Transsphenoidal Surgery for Cushing Disease After Nondiagnostic Inferior Petrosal Sinus Sampling. Neurosurgery, 2012, 71, 14-22.	1.1	28
53	Adrenally Directed Medical Therapies for Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 16-25.	3.6	28
54	Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e532-e543.	3.6	27

#	Article	IF	CITATIONS
55	Syndromes of Severe Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3025-3030.	3.6	27
56	A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: a KIMS database analysis. European Journal of Endocrinology, 2012, 167, 343-351.	3.7	26
57	Low Plasma Oxytocin Levels and Increased Psychopathology in Hypopituitary Men With Diabetes Insipidus. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3181-3191.	3.6	26
58	Diagnosis and Treatment of Acromegaly: An Update. Mayo Clinic Proceedings, 2022, 97, 333-346.	3.0	26
59	Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis. Endocrine, 2018, 59, 39-49.	2.3	25
60	Serum monocyte chemoattractant protein-1 is increased in chronic autoimmune thyroiditis. Metabolism: Clinical and Experimental, 2002, 51, 1489-1493.	3.4	24
61	Medical management of Cushing's disease. Journal of Neuro-Oncology, 2014, 117, 407-414.	2.9	23
62	MANAGEMENT OF ENDOCRINE DISEASE: Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry?. European Journal of Endocrinology, 2018, 179, R287-R296.	3.7	23
63	Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion. 2013. 60. 358-367.	0.8	21
64	Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. European Journal of Endocrinology, 2017, 176, 213-220.	3.7	21
65	Medical Therapy for Cushing's Syndrome in the Twenty-first Century. Endocrinology and Metabolism Clinics of North America, 2018, 47, 427-440.	3.2	21
66	Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem. Endocrine Practice, 2020, 26, 340-353.	2.1	21
67	Focus on growth hormone deficiency and bone in adults. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 49-57.	4.7	20
68	Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Pituitary, 2017, 20, 129-135.	2.9	20
69	Advances in the Medical Treatment of Cushing Disease. Endocrinology and Metabolism Clinics of North America, 2020, 49, 401-412.	3.2	20
70	Current concepts of the diagnosis of adult growth hormone deficiency. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 109-116.	5.7	20
71	Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2271-e2281.	3.6	19
72	Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. Journal of Comparative Neurology, 1998, 402, 442-459.	1.6	19

#	Article	IF	CITATIONS
73	Rapid Improvement of Osteoporosis Following Parathyroidectomy in a Premenopausal Woman With Acute Primary Hyperparathyroidism. Archives of Internal Medicine, 1999, 159, 1495.	3.8	18
74	Characterization of [Phe13, Tyr19]-MCH analog binding activity to the MCH receptor. Neuropeptides, 2000, 34, 240-247.	2.2	18
75	The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly. Pituitary, 2014, 17, 366-373.	2.9	18
76	Diagnostic and Therapeutic Approach to Pituitary Incidentalomas. Endocrine Practice, 2004, 10, 438-444.	2.1	17
77	Growth Hormone Therapy in Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction: a Meta-Analysis. Endocrine Practice, 2008, 14, 40-49.	2.1	17
78	Pathologic and clinical features of pituitary adenomas showing TSH immunoreactivity. Pituitary, 2013, 16, 287-293.	2.9	14
79	MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands. Pituitary, 2020, 23, 212-222.	2.9	14
80	Neurosurgical Treatment of Cushing Disease. Neurosurgery Clinics of North America, 2012, 23, 639-651.	1.7	13
81	Predictors of the effects of 4Âyears of growth hormone replacement on bone mineral density in patients with adultâ€onset growth hormone deficiency – a <scp>KIMS</scp> database analysis. Clinical Endocrinology, 2013, 79, 178-184.	2.4	13
82	Endocrine manifestations of Erdheim-Chester disease (a distinct form of histiocytosis). Journal of Internal Medicine, 1998, 244, 529-35.	6.0	13
83	Hypercalcemia in an AIDS patient treated with growth hormone. Aids, 1997, 11, 1353-1356.	2.2	12
84	Discovery of Cushing's Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients. Obesity Surgery, 2015, 25, 2306-2313.	2.1	12
85	The comprehensive impact on human body induced by resolution of growth hormone excess. European Journal of Endocrinology, 2018, 178, 365-375.	3.7	12
86	Medical Management of Cushing Disease. Neurosurgery Clinics of North America, 2019, 30, 499-508.	1.7	12
87	Impaired Bone Microarchitecture in Premenopausal Women With Acromegaly: The Possible Role of Wnt Signaling. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2690-2706.	3.6	12
88	All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. European Journal of Endocrinology, 2020, 182, 285-292.	3.7	11
89	Comparative Efficacy of Medical Treatment for Acromegaly: A Systematic Review and Network Meta-Analysis of Integrated Randomized Trials and Observational Studies. Endocrine Practice, 2020, 26, 454-462.	2.1	11
90	Role of Leptin in the Development of Cardiac Hypertrophy in Experimental Animals and Humans. Circulation, 2004, 109, e67; author reply e67.	1.6	10

#	Article	IF	CITATIONS
91	Characterization of cyclic Cushing's disease using late night salivary cortisol testing. Clinical Endocrinology, 2018, 89, 336-345.	2.4	10
92	Case 40-2011. New England Journal of Medicine, 2011, 365, 2520-2530.	27.0	9
93	Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness. EndocrinologÃa Y Nutrición (English Edition), 2013, 60, 358-367.	0.5	9
94	Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center. Pituitary, 2016, 19, 437-447.	2.9	9
95	Adult growth hormone deficiency: Optimizing transition of care from pediatric to adult services. Growth Hormone and IGF Research, 2021, 56, 101375.	1.1	9
96	A patient with diabetes insipidus, anterior hypopituitarism and pituitary stalk thickening. Nature Reviews Endocrinology, 2011, 7, 54-59.	9.6	8
97	Neuroendocrine disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 136, 873-885.	1.8	8
98	Prolactin and Its Role in Human Reproduction. , 2019, , 58-74.e8.		8
99	Lower Oxytocin Levels Are Associated with Lower Bone Mineral Density and Less Favorable Hip Geometry in Hypopituitary Men. Neuroendocrinology, 2021, 111, 87-98.	2.5	8
100	Clinical Outcomes and Self-Reported Symptoms in Patients With Acromegaly: An 8-Year Follow-Up of a Lanreotide Study. Endocrine Practice, 2017, 23, 56-65.	2.1	7
101	Cushing's disease in older patients: Presentation and outcome. Clinical Endocrinology, 2018, 89, 444-453.	2.4	7
102	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. Pituitary, 2022, 25, 64-73.	2.9	7
103	Hyperprolactinemia. JAMA - Journal of the American Medical Association, 2015, 314, 1742.	7.4	6
104	The Utility of Intraoperative Cytological Smear and Frozen Section in the Surgical Management of Patients with Cushing's Disease due to Pituitary Microadenomas. Endocrine Pathology, 2019, 30, 180-188.	9.0	6
105	High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1075-e1084.	3.6	6
106	Diagnosis of primary aldosteronism in a patient with an incidentally found adrenal mass. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 547-551.	2.8	5
107	Traumatic Brain Injury: Effects on the Endocrine System. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 27A-28A.	3.6	5
108	Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly. Clinical Endocrinology, 2021, 94, 58-65.	2.4	5

#	Article	IF	CITATIONS
109	Hypothyroidism in Two Patients after Hepatic Arterial Chemoembolization. Annals of Internal Medicine, 2001, 134, 535.	3.9	4
110	Effect of raloxifene on aortic elasticity in healthy postmenopausal women. American Heart Journal, 2005, 150, 1212.e1-1212.e6.	2.7	4
111	Cavernous Carotid Artery Aneurysm, a Rare Cause of Intrasellar Mass and Hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 723-724.	3.6	4
112	Is there a role for targeted medical therapies in patients with craniopharyngiomas?. Future Oncology, 2015, 11, 3221-3223.	2.4	4
113	Growth hormone deficiency in adults with Cushing's disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101474.	4.7	4
114	Magnetic resonance imaging of the hypothalamo–pituitary region. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 95-112.	1.8	4
115	Museum Visit Leading to Insulin Pump Malfunction. Annals of Internal Medicine, 1997, 126, 746.	3.9	4
116	The Prolactin per Unit Tumor Volume Ratio Accurately Distinguishes Prolactinomas From Secondary Hyperprolactinemia due to Stalk Effect. Endocrine Practice, 2022, 28, 572-577.	2.1	4
117	Quality of life after long-term biochemical control of acromegaly. Pituitary, 2022, 25, 531-539.	2.9	4
118	Skeletal health in adult growth hormone deficiency. Endocrine, 2016, 52, 1-2.	2.3	3
119	Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. , 1998, 402, 442.		3
120	The role of pasireotide in the treatment of acromegaly. Lancet Diabetes and Endocrinology,the, 2014, 2, 855-856.	11.4	2
121	Endocrine manifestations of Erdheim-Chester disease (a distinct form of histiocytosis). Journal of Internal Medicine, 1998, 244, 529-535.	6.0	2
122	Left ventricular dilatation in normotensive, extremely overweight Japanese professional Sumo wrestlers. American Journal of Cardiology, 2003, 92, 1141.	1.6	1
123	Visual Vignette. Endocrine Practice, 2004, 10, 517.	2.1	1
124	Adiposity Contributes to Differences in Left Ventricular Structure and Diastolic Function with Age in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1485-1485.	3.6	1
125	Serum dehydroepiandrosterone sulfate in the diagnosis of adrenal insufficiency: ready for prime time?. Endocrine Practice, 2011, 17, 167-169.	2.1	1
126	Medical Therapies in Cushing's Syndrome. , 2017, , 165-179.		1

8

0

#	Article	IF	CITATIONS
127	How concerned should we be over the long-term safety of growth hormone therapy?. Lancet Diabetes and Endocrinology,the, 2017, 5, 79-81.	11.4	1
128	Setting the Bar High for the Care of Patients With Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1895-e1896.	3.6	1
129	Cure of Cushing's Disease: Still an Elusive Goal?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e367-e369.	3.6	1
130	Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. , 1998, 402, 442.		1
131	SUN-455 Abnormalities in Bone Microarchitecture of Women with Active Acromegaly Using HR-pQCT. Journal of the Endocrine Society, 2019, 3, .	0.2	1
132	Recurrent Acromegaly in a Patient With a CHEK2 Mutation. AACE Clinical Case Reports, 2022, 8, 85-88.	1.1	1
133	Authors' Response: Adiposity Contributes to Differences in Left Ventricular Structure and Diastolic Function with Age in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1485-1486.	3.6	0
134	Letters to the editor. European Heart Journal, 2005, 26, 201-202.	2.2	0
135	Dizzy and Red-faced. American Journal of Medicine, 2007, 120, 412-414.	1.5	0
136	Evaluation and management of thyrotropin-secreting pituitary adenomas. International Journal of Endocrine Oncology, 2014, 1, 163-171.	0.4	0
137	Recent advances in medical therapies for pituitary adenomas. International Journal of Endocrine Oncology, 2017, 4, 151-154.	0.4	0
138	Epidemiology and Etiology of Cushing's Disease. , 2017, , 43-56.		0
139	MRI Texture Analysis as a Predictor of Tumor Recurrence or Progression in Patients with Clinically Non-Functioning Pituitary Adenomas. Canadian Journal of Diabetes, 2018, 42, S3.	0.8	0
140	OR32-05 Lower Oxytocin Levels Are Associated with Lower Bone Mineral Density and Less Favorable Hip Geometry in Hypopituitary Men. Journal of the Endocrine Society, 2020, 4, .	0.2	0
141	Changes in Quality of Life After Long-Term Biochemical Control of Acromegaly. Journal of the Endocrine Society, 2021, 5, A639-A640.	0.2	0
142	Cyclic Cushing's Disease. Growth Hormone, 2011, , 71-83.	0.2	0
143	15. A 37-year-old Woman with a Sellar Mass. , 2013, , 93-95.		0

144 Management of Cushing's Disease. , 2018, , 39-49.

9

#	Article	IF	CITATIONS
145	Radiation Therapy in Patients With Cushing Disease. , 2019, , 237-242.		0
146	Cushing's Syndrome. , 2020, , 215-227.		0
147	SAT-LB11 Adult Growth Hormone Deficiency Transition Care From Pediatric to Adult Services: Insights From a US Advisory Board. Journal of the Endocrine Society, 2020, 4, .	0.2	0